BCA
TXMD icon

Bay Colony Advisors’s TherapeuticsMD TXMD Stock Holding History

Bay Colony Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-12,704
Closed -$673K – 220
2020
Q1 		$673K Buy
12,704
+2,000
+19% +$198K 0.61% 56
2019
Q4 		$1.45M Hold
10,704
– – 0.94% 15
2019
Q3 		$1.94M Buy
+10,704
New +$1.51M 1.32% 7

Other funds holding TXMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bay Colony Advisors's TXMD Position: Q2 2020 in Review

Bay Colony Advisors sold out of TherapeuticsMD (TXMD) in Q2 2020, closing a stake of 12,704 shares — an estimated $673K sold.

Bay Colony Advisors first reported a position in TXMD in Q3 2019 and held it in 3 quarters. The position peaked at $1.94M in Q3 2019. 149 funds tracked by Wall St. Rank hold TXMD as of Q2 2020.

  • Bay Colony Advisors reported no remaining TherapeuticsMD position as of Q2 2020 after selling out during the quarter.
  • Bay Colony Advisors sold 12,704 TherapeuticsMD shares in Q2 2020, an estimated $673K.
  • Bay Colony Advisors first reported a position in TherapeuticsMD in Q3 2019 and held it in 3 quarters.
  • Bay Colony Advisors's TherapeuticsMD position peaked at $1.94M in Q3 2019.
  • 149 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2020.

Based on Bay Colony Advisors's 13F filing for Q2 2020, filed 23 Jul 2020.